1. Home
  2. Analysis
  3. Abraxane
  4. Everolimus

Abraxane and Everolimus drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Abraxane (paclitaxel) and Everolimus (everolimus). Common drug interactions include metastases to liver among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Abraxane and Everolimus. It is created by eHealthMe based on reports of 60 people who take the same drugs from the FDA, and is updated regularly.

What is Abraxane?

Abraxane has active ingredients of paclitaxel. It is often used in breast cancer metastatic. eHealthMe is studying from 19,196 Abraxane users. Check the latest studies of Abraxane.

What is Everolimus?

Everolimus has active ingredients of everolimus. eHealthMe is studying from 16,228 Everolimus users. Check the latest studies of Everolimus.

On Jul, 29, 2026

60 people who take Abraxane and Everolimus together, and have interactions are studied.

Abraxane and Everolimus drug interactions.

What are the common drug interactions of Abraxane and Everolimus, by gender? *:

female:

  1. Metastases to liver (cancer spreads to liver)
  2. Neutropenia (an abnormally low number of neutrophils)
  3. Metastases to lymph nodes (cancer spreads to lymph node)
  4. Diplopia (double vision)
  5. Metastases to bladder (cancer spreads to bladder)
  6. Metastases to central nervous system (cancer spreads to central nervous system)
  7. Urinary tract disorder
  8. Vertigo
  9. Diarrhoea
  10. Fatigue (feeling of tiredness)

male:

  1. Death
  2. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  3. Fungal infection
  4. General physical health deterioration (weak health status)
  5. Pancreatic carcinoma metastatic (pancreatic cancer- metastatic)
  6. Pneumonia
  7. Pulmonary embolism (blockage of the main artery of the lung)
  8. Tracheostomy infection (infection of trachea surgical opening)

What are the common drug interactions of Abraxane and Everolimus, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Pulmonary haemorrhage (acute bleeding from the lung)
  2. Malignant neoplasm progression (cancer tumour came back)
  3. Metastases to bone (cancer spreads to bone)
  4. Metastases to liver (cancer spreads to liver)
  5. Metastases to lung (cancer spreads to lung)
  6. Pulmonary embolism (blockage of the main artery of the lung)
  7. Pulmonary mass

40-49:

  1. Malignant neoplasm progression (cancer tumour came back)
  2. Metastases to bone (cancer spreads to bone)
  3. Arthralgia (joint pain)
  4. Chondromalacia (anterior knee pain due to irritation of the cartilage on the under surface of the kneecap)
  5. Device related infection
  6. Diarrhoea
  7. Dysgeusia (disorder of the sense of taste)
  8. Dyspnoea (difficult or laboured respiration)
  9. Fatigue (feeling of tiredness)
  10. Infection

50-59:

  1. Neutropenia (an abnormally low number of neutrophils)
  2. Malignant neoplasm progression (cancer tumour came back)
  3. Metastases to bone (cancer spreads to bone)
  4. Metastases to lymph nodes (cancer spreads to lymph node)
  5. Diarrhoea
  6. Osteonecrosis of jaw (death of bone of jaw)
  7. Anaemia (lack of blood)
  8. Asthenia (weakness)
  9. Nausea (feeling of having an urge to vomit)
  10. Thrombocytopenia (decrease of platelets in blood)

60+:

  1. Metastases to bone (cancer spreads to bone)
  2. Metastases to liver (cancer spreads to liver)
  3. Back pain
  4. Bone lesion (bone with abnormalities. bone lesions can result from growth formations, infections, or injuries)
  5. Breast cancer stage iv
  6. Carbohydrate antigen 15-3 increased
  7. Disease progression
  8. Metastases to spine (cancer spreads to spine)
  9. Neoplasm progression (growth of tumour)
  10. Neuropathy peripheral (surface nerve damage)

What are the existing conditions these people have? *

  1. Breast Cancer: 18 people, 30.00%
  2. Radiation Pneumonitis (inflammation of lung due to radiation): 3 people, 5.00%
  3. Pulmonary Embolism (blockage of the main artery of the lung): 3 people, 5.00%
  4. Iron Deficiency Anaemia: 3 people, 5.00%
  5. High Blood Pressure: 3 people, 5.00%
  6. Device Related Infection: 3 people, 5.00%
  7. Depression: 3 people, 5.00%
  8. Breast Cancer Stage Iii: 3 people, 5.00%
  9. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Abraxane and Everolimus?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Abraxane and Everolimus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Abraxane:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Everolimus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Abraxane and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Everolimus and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on paclitaxel and everolimus (the active ingredients of Abraxane and Everolimus, respectively), and Abraxane and Everolimus (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.